| Popis: |
Background: Therapeutic cannabinoids are derived from marijuana, a plant of the cannabis genus. Cannabis sativa and Cannabis indica are the two main species. Cannabis plants contain more than 100 cannabinoids, but the biologically active and therapeutically researched ones are 9 tetrahydrocannabinol (THC) and cannabinol (CBD). Cannabinoids have been advocated for a number of neurological and psychiatric disorders, including multiple sclerosis, mood disorders, schizophrenia, Parkinson’s disease, dystonia, neuropathic pain, nausea, anorexia and epilepsy. Epilepsy is a chronic disease characterized by recurrent unprovoked seizures, affecting more than 50 million people worldwide, in the pediatric age group, with childhood epilepsy being one of the most serious and developing epileptic encephalopathies. Objective: In view of the above, the present study proposed to review the use of cannabidiol in the treatment of epilepsy in neuropediatric, with sources published between 2016-2020. Methods: To perform this research, PubMed (https://pubmeed.ncbi.nlm.nih. gov/) and Scielo (https://www.scielo.org/) databases were used as a search tool, using the Key words “Cannabidiol”, “Epilepsy”, “Cannabis” and “Children”. Results: So far, 11 articles related to the study have been identified, the vast majority being reviewed, with 9 articles obtained from PubMed and 2 acquired from Scielo. Selected articles show that CBD is an effective anticonvulsant in many acute animal models, but its antiepileptic mechanisms are not yet fully recognized. In studies with children in Canada and the United States, they suggest an improvement in the frequency of seizures and an improvement in quality of life, but the numbers are still small. Studies report that CBD is well tolerated, however, it causes sedation, diarrhea and decreased appetite. Conclusions: It is necessary to investigate the safety, pharmacokinetics and interaction between drugs already used by patients and CBD, also conducting more double-blind placebo-controlled trials to obtain conclusive data on their efficacy and safety in the most frequent epilepsies in children. |
